Lonza Netherlands, former PharmaCell

Lonza Netherlands, former PharmaCell

Lonza Netherlands is a Contract Manufacturing Organization (CMO) in the area of cell therapy and regenerative medicine (tissue culturing). Founded in 2005, the company operates two state-of-the-art cGMP-licensed facilities for human cell & tissue culturing in Maastricht and Geleen (Netherlands). They work with European and US-based biotechnology companies on pre-clinical, clinical to commercial development projects. Their services include GMP and regulatory consultancy, cell culturing process development, fill and finish, Quality Control (QC)-testing, and Good Manufacturing Practices (GMP) production services, as well as storage and distribution of clinical trial materials.

The recent €2.00M Venture Round investment at 28 February 2007 from Limburg Startup and Maastricht University demonstrates confidence in Lonza Netherlands' capabilities and potential for growth in the fast-evolving cell therapy and regenerative medicine industry. With its strategic location in the center of Europe, Lonza Netherlands is well-positioned to serve its clients, located approximately one hour driving distance from Brussels, Antwerp, Cologne, and Dusseldorf.

The company operates in the Fashion and Manufacturing industries, offering essential support and facilities for the development and production of advanced therapies. Lonza Netherlands' expertise and infrastructure make it an attractive investment opportunity in the burgeoning field of cell therapy and regenerative medicine.